Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Peter Clark, MA, MD, FRCP: A Payer Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Oct
10
Today In Oncology
HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy
FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC
FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer
Cancer Statistics 2026: Incidence, Mortality, Survival, and Disparities in U.S. Oncology
FDA Approves First-Line Pirtobrutinib for CLL-SLL
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo